The two faces of mast cells in vitiligo pathogenesis

Abstract

Aim: Previously, we reported increased number of T helper 17 (Th17) cells in vitiligo. However, in our recent study, tryptase and interleukin (IL)17 double positive cells which identified by polyclonal anti-IL17 antibody with specificity for IL17A, B, D, F was observed, but these mast cells cannot be stained by monoclonal anti-IL17 antibody with specificity for IL17A. Therefore, this study was aimed to clarify the role of mast cells in induction and progression of vitiligo.
Methods: Mast cells were stained with two antibodies against IL17 and one antibody against tryptase by immunofluorescent staining. Furthermore, immunoelectron microscopy (IEM) analyses were conducted using anti-tryptase. In vitro, cultured epidermal keratinocytes were treated with agents which released by mast cells. Expression levels of mRNA were analyzed by real-time polymerase chain reaction (PCR), expression of protein levels was analyzed by western blotting.
Results: An increased number of tryptase positive mast cells was observed at the lesional skin of upper dermis in vitiligo and rhododendrol-induced leukoderma (RDIL). These mast cells showed prominent degranulation in vitiligo. Interestingly, the melanosome forming glycoprotein non-metastatic melanoma protein B (GPNMB) is downregulated in the lesional basal keratinocytes in vitiligo and mast cell tryptase contributes to this phenomenon. In addition, small interfering GPNMB RNA (siGPNMB RNA)-introduced keratinocytes increased melanocyte survival through stem cell factor (SCF) production in the melanocyte/keratinocyte co-culture system.
Conclusions: Mast cells might be two-faced in vitiligo induction, progression, and recovery through the differential function of histamine and tryptase.

Keywords

Vitiligo / rhododendrol-induced leukoderma / mast cell / tryptase / interleukin 17

References

[1] Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 2002; 15: 87-92.

[2] Singh M, Kotnis A, Jadeja SD, Mondal A, Mansuri MS, Begum R. Cytokines: the yin and yang of vitiligo pathogenesis. Expert Rev Clin Immunol. 2019; 15: 177-88.

[3] Khan R, Gupta S, Sharma A. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo. J Am Acad Dermatol. 2012; 66: 510-1.

[4] Seneschal J, Boniface K, D’Arino A, Picardo M. An update on vitiligo pathogenesis. Pigment Cell Melanoma Res. 2021; 34: 236-43.

[5] Matsunaga K, Suzuki K, Ito A, Tanemura A, Abe Y, Suzuki T, et al. Rhododendrol-induced leukoderma update I: clinical findings and treatment. J Dermatol. 2021; 48: 961-8.

[6] Nishigori C, Aoyama Y, Ito A, Suzuki K, Suzuki T, Tanemura A, et al. Guide for medical professionals (i.e., dermatologists) for the management of rhododenol-induced leukoderma. J Dermatol. 2015; 42: 113-28.

[7] Yasuda M, Sekiguchi A, Kishi C, Toki S, Arase N, Takahashi A, et al. Immunohistochemical analysis of rhododendrol-induced leukoderma in improved and aggravated cases. J Dermatol Sci. 2020; 99: 140-3.

[8] Yoshida M, Hirotsu S, Nakahara M, Uchiwa H, Tomita Y. Histamine is involved in ultraviolet B-induced pigmentation of guinea pig skin. J Invest Dermatol. 2002; 118: 255-60.

[9] Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H, et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res. 2012; 25: 219-30.

[10] Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Canete JD, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012; 64: 99-109.

[11] Yang F, Yang L, Teng L, Zhang H, Katayama I. Morphological alterations and increased S100B expression in epidermal langerhans cells detected in skin from patients with progressive vitiligo. Life (Basel). 2021; 11: 579.

[12] Yang F, Yang L, Wataya-Kaneda M, Yoshimura T, Tanemura A, Katayama I. Uncoupling of ER/mitochondrial oxidative stress in mTORC1 hyperactivation-associated skin hypopigmentation. J Invest Dermatol. 2018; 138: 669-78.

[13] Jung SJ, Song H, Kim YY, Kim J, Kim S, Song YK, et al. Distribution of mast cells and locations, depths, and sizes of the putative acupoints CV 8 and KI 16. Evid Based Complement Alternat Med. 2017; 2017: 2953278.

[14] Biswas KB, Takahashi A, Mizutani Y, Takayama S, Ishitsuka A, Yang L, et al. GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin. Sci Rep. 2020; 10: 4930.

[15] Yang L, Yang F, Wataya-Kaneda M, Tanemura A, Tsuruta D, Katayama I. 4-(4-Hydroroxyphenyl)-2-butanol (rhododendrol) activates the autophagy-lysosome pathway in melanocytes: insights into the mechanisms of rhododendrol-induced leukoderma. J Dermatol Sci. 2015; 77: 182-5.

[16] Picardo M, Dell’Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, et al. Vitiligo. Nat Rev Dis Primers. 2015; 1: 15011.

[17] Riding RL, Harris JE. The role of memory CD8⁺ T cells in vitiligo . J Immunol. 2019; 203: 11-9.

[18] Hachiya A, Kobayashi A, Yoshida Y, Kitahara T, Takema Y, Imokawa G. Biphasic expression of two paracrine melanogenic cytokines, stem cell factor and endothelin-1, in ultraviolet B-induced human melanogenesis. Am J Pathol. 2004; 165: 2099-109.

[19] Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin . J Invest Dermatol. 2012; 132: 1869-76.

[20] Ghosh S. Chemical vitiligo: a subset of vitiligo. Indian J Dermatol. 2020; 65: 443-9.

[21] Inoue S, Katayama I, Suzuki T, Tanemura A, Ito S, Abe Y, et al. Rhododendrol-induced leukoderma update II: pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo. J Dermatol. 2021; 48: 969-78.

[22] Tomihari M, Hwang SH, Chung JS, Cruz PD, jr, Ariizumi K. Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol. 2009; 18: 586-95.

[23] Enomoto A, Yoshihisa Y, Yamakoshi T, Ur Rehman M, Norisugi O, Hara H, et al. UV-B radiation induces macrophage migration inhibitory factor-mediated melanogenesis through activation of protease-activated receptor-2 and stem cell factor in keratinocytes. Am J Pathol. 2011; 178: 679-87.

[24] Kapoor R, Dhatwalia SK, Kumar R, Rani S, Parsad D. Emerging role of dermal compartment in skin pigmentation: comprehensive review. J Eur Acad Dermatol Venereol. 2020; 34: 2757-65.

[25] Liu J, Xu Y, Lin TK, Lv C, Elias PM, Man MQ. Topical histamine stimulates repigmentation of nonsegmental vitiligo by a receptor-dependent mechanism. Skin Pharmacol Physiol. 2017; 30: 139-45.

[26] Zhuang T, Li S, Yi X, Guo S, Wang Y, Chen J, et al. Tranilast directly targets NLRP3 to protect melanocytes from keratinocyte-derived IL-1β under oxidative stress. Front Cell Dev Biol. 2020; 8: 588.

[27] Yamamoto A, Yang L, Kuroda Y, Guo J, Teng L, Tsuruta D, et al. Local epidermal endocrine estrogen protects human melanocytes against oxidative stress, a novel insight into vitiligo pathology. Int J Mol Sci. 2020; 22: 269.

[28] Yang L, Yang F, Teng L, Katayama I. 6-Shogaol protects human melanocytes against oxidative stress through activation of the Nrf2-antioxidant response element signaling pathway. Int J Mol Sci. 2020; 21: 3537.

[29] Yang L, Wong PM, Yang L, Katayama I, Wu H, Zhang H. Electrocautery needling and the 308-nm excimer lamp: a synergistic combination for the treatment of stable non-segmental vitiligo. Dermatol Ther (Heidelb). 2020; 10: 695-705.

[30] Yang L, Wong PM, Yang L, Katayama I, Wu H, Zhang H. Vitiligo effectively treated with electrocautery needling technique. Dermatol Ther. 2020; 33: e14154.

[31] Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev. 2007; 217: 65-78.

[32] Woolley DE, Tetlow LC. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2000; 2: 65-74.